Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Type 2 Diabetes
Interventions: MEDI-4166, Placebo; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Anniston, Alabama • Chula Vista, California • Jacksonville, Florida + 7 more

Conditions: Acquired Thrombotic Thrombocytopenic Purpura
Interventions: Caplacizumab, Placebo; Biological
Lead sponsor: Ablynx, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more

Conditions: Alzheimer Disease, Healthy
Interventions: LY3372993, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 139 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Cypress, California • Long Beach, California • DeLand, Florida + 6 more

Conditions: Breakthrough Pain
Interventions: Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Tendinopathy
Interventions: SM04755, Vehicle; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Avenanthramide-enriched oats; Other
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Rodatristat Ethyl, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Endometrial Biopsy
Interventions: COL-1077, Placebo; Drug
Lead sponsor: Juniper Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 23
States / cities: Norwalk, California • Colorado Springs, Colorado • Lakewood, Colorado + 19 more

Conditions: Hypertension
Interventions: baxdrostat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Tuberculosis
Interventions: PNU-100480, Placebo; Drug
Lead sponsor: Sequella, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Adults
Interventions: Modafinil, placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 35 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Generalized Anxiety Disorder (GAD), Healthy Participants
Interventions: ABBV-932, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Health Adult Subjects, Obesity & Overweight
Interventions: TIX100, Placebo; Drug
Lead sponsor: TIXiMED, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions: Placebo, Silymarin; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 5
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Intoxication Alcohol, Intoxication THC, Intoxication Combined Alcohol THC
Interventions: Dronabinol, Ethanol, Placebo dronabinol, Placebo ethanol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 316 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease
Interventions: MEDI6012, Placebo SC, Placebo IV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 5 more

Conditions: Social Anxiety, Social Anxiety Disorder
Interventions: Cannabidiol, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Osteoarthritis, Knee Pain
Interventions: SL-1002, Placebo; Drug
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 35 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Greenwood Village, Colorado • Washington D.C., District of Columbia • Coral Gables, Florida + 12 more

Conditions: Major Depression
Interventions: Psilocybin (Usona Institute), Propofol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Venous Thromboembolism
Interventions: Semuloparin sodium, Enoxaparin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Ebola Hemorrhagic Fever
Interventions: Placebo, AVI-6002; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy Volunteers
Interventions: SB26, Placebo; Drug
Lead sponsor: Samsung Bioepis Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Malaria
Interventions: MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg; Biological · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

Staccato Fentanyl Single and Multidose PK

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects

Bioavailability of Avenanthramide-Enriched Oats in Healthy Older Adults

A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety

COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

Modafinil Effects on EEG Biomarkers of Reward and Motivation

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

Phase I Trial of Silymarin for Chronic Liver Diseases

Using Imaging to Assess Effects of THC on Brain Activity

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Cannabidiol to Reduce Anxiety Reactivity

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

Study of Psilocybin Under Anesthesia Controlled by EEG

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

A Phase I Study of SB26 in Healthy Volunteers

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Intravenous Ketamine for Treatment-Resistant Depression